Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes

Executive Summary

Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.

You may also be interested in...



Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE

Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.

Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile

Merck & Co and Pfizer release new combo data for their investigational SGLT2 inhibitor at the ADA – combinations will be key to the latecomer's overall success.

Novo Nordisk Sharpens Its Outlook But Warns Risks Remain Later In 2017

A robust first quarter allowed the Danish diabetes fighter to tighten its guidance - but things are likely to get bumpier for the troubled group as the year progresses.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel